Lipocine (NASDAQ:LPCN) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research report sent to investors on Monday morning.

Separately, Alliance Global Partners started coverage on Lipocine in a research note on Tuesday, September 24th. They set a buy rating and a $10.00 price objective for the company.

Lipocine Stock Performance

Shares of NASDAQ:LPCN opened at $5.11 on Monday. The company has a market cap of $27.30 million, a P/E ratio of -2.99 and a beta of 1.22. Lipocine has a one year low of $2.31 and a one year high of $11.79. The business’s 50-day simple moving average is $4.26 and its 200 day simple moving average is $5.60.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The company had revenue of $0.09 million during the quarter. Analysts predict that Lipocine will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.